Morgan Stanley Genetic Technologies LTD Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.7 - $0.93 $489 - $651	-700 Reduced 0.79%	87,656 $66,000
Q2 2023 Aug 14, 2023	SELL	$0.8 - $1.13 $10,978 - $15,506	-13,723 Reduced 13.44%	88,356 $73,000
Q1 2023 May 15, 2023	BUY	$0.86 - $1.82 $44,634 - $94,458	51,900 Added 103.43%	102,079 $118,000
Q4 2022 Feb 14, 2023	SELL	$0.93 - $6.18 $1,999 - $13,287	-2,150 Reduced 4.11%	50,179 $46,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $6.4 $0 - $1,280	-200 Reduced 0.38%	52,329 $62,000
Q2 2022 Oct 27, 2022	BUY	$0.0 - $0.01 $0 - $254	25,400 Added 93.63%	52,529 $61,000
Q2 2022 Aug 15, 2022	BUY	$0.0 - $0.01 $0 - $254	25,400 Added 93.63%	52,529 $61,000
Q1 2022 Oct 27, 2022	SELL	$0.0 - $0.0 $0 - $0	-25,400 Reduced 48.35%	27,129 $54,000
Q1 2022 May 13, 2022	SELL	$0.0 - $0.0 $0 - $0	-32,492 Reduced 54.5%	27,129 $54,000
Q4 2021 Feb 14, 2022	BUY	$0.0 - $0.01 $0 - $295	29,508 Added 97.99%	59,621 $112,000
Q3 2021 Nov 15, 2021	BUY	$0.0 - $0.01 $0 - $301	30,113 New	30,113 $93,000

Ticker GENE
Exchange OTC
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 15,389,900
Market Cap $11.5M
Description
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.